All > Montreal > Velcade

CC-92480 for Multiple Myeloma

Local Institution - 0004, Waratah, Australia
Multiple MyelomaCC-92480 - Drug
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

This trial is testing a new combo - CC-92480, bortezomib, and dexamethasone - against the standard of care - pomalidomide, bortezomib, and dexamethasone - for patients with multiple myeloma who have failed 1-3 prior treatments and have been treated with lenalidomide before.

Eligible Conditions
  • Relapsed or Refractory Multiple Myeloma

Treatment Effectiveness

Phase-Based Effectiveness

2 of 3
Phase 3
This is further along than 85% of similar trials

Similar Trials

1
Isatuximab
1
CIML NK Cells plus KP1237 and low dose IL-2
1
CC-92480

Study Objectives

1 Primary · 15 Secondary · Reporting Duration: Up to approximately 5 years

Year 5
Overall Survival (OS)
Year 5
Progression-free Survival (PFS)
Up to 12 Months
Recommended CC- 92480 dose
Up to 134 Days
Plasma concentrations of CC-92480
Year 5
Percentage of participants with Complete Response Rate (CRR) or better as assessed by the International Myeloma Working Group (IMWG) Uniform Response Criteria for Multiple Myeloma
Year 5
Change from baseline in European Organization for Research and Treatment of Cancer - Quality of Life C30 questionnaire (EORTC QLQ-C30) scores
Change from baseline in European Organization for Research and Treatment of Cancer - Quality of Life Multiple Myeloma Module (EORTC QLQ-MY20) score
Duration of Response (DOR)
Neoplasm, Residual
Number of participants with Adverse Events (AEs)
Overall Response Rate (ORR)
Percentage of participants with Very Good Partial Response Rate (VGPRR) or better as assessed by the IMWG Uniform Response Criteria for Multiple Myeloma
Progression-free Survival 2 (PFS-2)
Therapeutic procedure
Time to Progression (TTP)
Time to Response (TTR)

Trial Safety

Phase-Based Safety

3 of 3
This is further along than 85% of similar trials

Similar Trials

1
Isatuximab
1
CIML NK Cells plus KP1237 and low dose IL-2
1
CC-92480

Awards & Highlights

No Placebo Group
All patients enrolled in this trial will receive the new treatment.
Pivotal Trial
The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.

Trial Design

2 Treatment Groups

PVd (pomalidomide, bortezomib and dexamethasone)
1 of 2
480Vd (CC-92480, bortezomib and dexamethasone)
1 of 2

Experimental Treatment

760 Total Participants · 2 Treatment Groups

Primary Treatment: CC-92480 · No Placebo Group · Phase 3

PVd (pomalidomide, bortezomib and dexamethasone)Experimental Group · 3 Interventions: Bortezomib, Dexamethasone, Pomalidomide · Intervention Types: Drug, Drug, Drug
480Vd (CC-92480, bortezomib and dexamethasone)Experimental Group · 3 Interventions: Bortezomib, Dexamethasone, CC-92480 · Intervention Types: Drug, Drug, Drug
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Bortezomib
2005
Completed Phase 2
~1140
Dexamethasone
2007
Completed Phase 4
~2420
CC-92480
2018
Completed Phase 1
~150
Pomalidomide
2011
Completed Phase 2
~1330

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: up to approximately 5 years

Who is running the clinical trial?

Bristol-Myers SquibbLead Sponsor
2,537 Previous Clinical Trials
4,018,506 Total Patients Enrolled
73 Trials studying Multiple Myeloma
14,951 Patients Enrolled for Multiple Myeloma

Eligibility Criteria

Age 18+ · All Participants · 0 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:

Who else is applying?

What state do they live in?
California100.0%
What portion of applicants met pre-screening criteria?
Did not meet criteria100.0%
References

Frequently Asked Questions

What has been observed in patients taking CC-92480?

"There is both preclinical and clinical evidence supporting CC-92480's safety, thus it received a score of 3." - Anonymous Online Contributor

Unverified Answer

Could you name how many places this research project is being conducted?

"Patients can be enrolled at the Local Institution in Hattiesburg, Mississippi, Utah Cancer Specialists in Salt Lake City, Utah, Northwell Health Clinical Trials Office in Lake Success, New York, and 18 other locations." - Anonymous Online Contributor

Unverified Answer

Can people sign up for this research project at the present moment?

"This study, as indicated on clinicaltrials.gov, is currently seeking participants. The trial was originally posted on September 20th, 2022 and was most recently updated on October 24th, 2022." - Anonymous Online Contributor

Unverified Answer
Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top